EGFR T790M mutation as a novel target for immunotherapy against EGFR-TKI-resistant non-small cell lung cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2051-1426
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
EGFR T790M mutation as a novel target for immunotherapy against EGFR-TKI-resistant non-small cell lung cancer ; volume:1 ; number:1 ; day:7 ; month:11 ; year:2013 ; pages:1 ; date:11.2013
Journal for ImmunoTherapy of Cancer ; 1, Heft 1 (7.11.2013), 1, 11.2013
- Urheber
-
Sasada, Tetsuro
- Beteiligte Personen und Organisationen
-
Yamada, Teppei
Azuma, Koichi
Matsueda, Satoko
Itoh, Kyogo
SpringerLink (Online service)
- DOI
-
10.1186/2051-1426-1-S1-P235
- URN
-
urn:nbn:de:1111-2016072652875
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:56 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Sasada, Tetsuro
- Yamada, Teppei
- Azuma, Koichi
- Matsueda, Satoko
- Itoh, Kyogo
- SpringerLink (Online service)
Ähnliche Objekte (12)
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer
Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant
EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non-small cell lung cancer
NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation
The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer
Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer
Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI
Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC
Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer
Osimertinib : Resistenz bei EGFR-mutiertem NSCL unter TKI-Behandlung
Postoperative survival of EGFR-TKI-targeted therapy in non-small cell lung cancer patients with EGFR 19 or 21 mutations: a retrospective study
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer
Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant
EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non-small cell lung cancer
NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation
The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer
Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer
Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI
Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC
Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer
Osimertinib : Resistenz bei EGFR-mutiertem NSCL unter TKI-Behandlung
Postoperative survival of EGFR-TKI-targeted therapy in non-small cell lung cancer patients with EGFR 19 or 21 mutations: a retrospective study
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer
Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant
EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non-small cell lung cancer
NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation
The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer
Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer
Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI
Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC
Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer
Osimertinib : Resistenz bei EGFR-mutiertem NSCL unter TKI-Behandlung